LAB · Standard Biotools Inc.
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -5.59M | Six Months Ended June 30, 2026 | — |
| Consumables revenue | $9.4M | the second quarter of 2026 | -10.1% |
|
|
|||
| Instruments revenue | $5.1M | the second quarter of 2026 | -2.2% |
|
|
|||
| Non-GAAP gross margin percentage non-GAAP | 57% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Non-GAAP operating expenses non-GAAP | 29.11M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Services revenue | $5.6M | the second quarter of 2026 | -8.0% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LAB
this stock
Standard Biotools Inc.
|
$252.00M | -49.9% | -2.4% | 2.9 | 0.6% |
|
ABT
Abbott Laboratories
|
$191.81B | -11.9% | +5.7% | 30.9 | 1.2% |
|
SYK
Stryker Corp
|
$126.84B | -5.9% | +11.2% | 34.3 | 1.8% |
|
MDT
Medtronic plc
|
$116.78B | -5.0% | +8.4% | 24.5 | 1.1% |
|
BSX
Boston Scientific Corp
|
$70.00B | -50.9% | +12.5% | 19.6 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LAB | -4.1% | -26.1% | -35.2% | -26.1% | -49.9% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -4.5% | -29.0% | -48.6% | -29.0% | -62.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.